[HLBANK] QoQ TTM Result on 31-Mar-2022 [#3]

Announcement Date
30-May-2022
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2022
Quarter
31-Mar-2022 [#3]
Profit Trend
QoQ- 0.44%
YoY- 12.06%
View:
Show?
TTM Result
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
Revenue 5,832,516 5,717,382 5,597,408 5,431,304 5,469,043 5,497,964 5,466,873 4.39%
PBT 4,722,690 4,511,819 4,366,800 3,974,083 3,884,049 3,622,802 3,470,939 22.72%
Tax -1,006,692 -1,099,379 -1,077,517 -902,956 -826,254 -632,812 -610,297 39.47%
NP 3,715,998 3,412,440 3,289,283 3,071,127 3,057,795 2,989,990 2,860,642 18.99%
-
NP to SH 3,715,998 3,412,440 3,289,283 3,071,127 3,057,795 2,989,990 2,860,642 18.99%
-
Tax Rate 21.32% 24.37% 24.68% 22.72% 21.27% 17.47% 17.58% -
Total Cost 2,116,518 2,304,942 2,308,125 2,360,177 2,411,248 2,507,974 2,606,231 -12.92%
-
Net Worth 32,079,791 31,156,802 31,006,211 30,351,463 30,062,673 29,448,800 29,461,726 5.82%
Dividend
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
Div 1,188,437 1,126,864 1,126,864 1,089,701 1,089,701 1,023,667 1,023,667 10.43%
Div Payout % 31.98% 33.02% 34.26% 35.48% 35.64% 34.24% 35.78% -
Equity
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
Net Worth 32,079,791 31,156,802 31,006,211 30,351,463 30,062,673 29,448,800 29,461,726 5.82%
NOSH 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 0.00%
Ratio Analysis
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
NP Margin 63.71% 59.69% 58.76% 56.54% 55.91% 54.38% 52.33% -
ROE 11.58% 10.95% 10.61% 10.12% 10.17% 10.15% 9.71% -
Per Share
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
RPS 284.72 279.11 273.13 265.20 267.06 268.28 267.02 4.35%
EPS 181.40 166.59 160.51 149.96 149.32 145.90 139.72 18.95%
DPS 58.00 55.00 55.00 53.22 53.22 50.00 50.00 10.37%
NAPS 15.66 15.21 15.13 14.82 14.68 14.37 14.39 5.78%
Adjusted Per Share Value based on latest NOSH - 2,167,718
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
RPS 269.06 263.75 258.22 250.55 252.29 253.63 252.19 4.39%
EPS 171.42 157.42 151.74 141.68 141.06 137.93 131.97 18.99%
DPS 54.82 51.98 51.98 50.27 50.27 47.22 47.22 10.43%
NAPS 14.7989 14.3731 14.3036 14.0016 13.8683 13.5852 13.5911 5.82%
Price Multiplier on Financial Quarter End Date
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
Date 30/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 -
Price 20.56 20.50 20.46 20.20 18.62 18.90 18.72 -
P/RPS 7.22 7.34 7.49 7.62 6.97 7.04 7.01 1.98%
P/EPS 11.33 12.31 12.75 13.47 12.47 12.95 13.40 -10.55%
EY 8.82 8.13 7.84 7.42 8.02 7.72 7.46 11.77%
DY 2.82 2.68 2.69 2.63 2.86 2.65 2.67 3.70%
P/NAPS 1.31 1.35 1.35 1.36 1.27 1.32 1.30 0.51%
Price Multiplier on Announcement Date
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
Date 28/02/23 29/11/22 30/08/22 30/05/22 28/02/22 29/11/21 30/08/21 -
Price 20.54 20.88 20.90 21.12 20.06 18.20 19.18 -
P/RPS 7.21 7.48 7.65 7.96 7.51 6.78 7.18 0.27%
P/EPS 11.32 12.53 13.02 14.08 13.43 12.47 13.73 -12.04%
EY 8.83 7.98 7.68 7.10 7.44 8.02 7.28 13.69%
DY 2.82 2.63 2.63 2.52 2.65 2.75 2.61 5.27%
P/NAPS 1.31 1.37 1.38 1.43 1.37 1.27 1.33 -1.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment